NEWTOWN, PA – December 16, 2014 – Helius Medical Technologies, Inc. (CSE: HSM) (“Helius”, or the “Company”) is pleased to announce today that the US Patent and Trademark Office (“USPTO”) issued a second broad patent related to the Portable Neuromodulation Stimulator (“PoNS™”) device and the associated therapeutic modality. The PoNSTM, an investigational medical device that induces neuromodulation by stimulating the cranial nerves found in the tongue, is initially being studied for the treatment of balance disorder symptoms caused by Traumatic Brain Injury (“TBI”) and MS.
U.S. Patent No. 8,909,345, “Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function”, issued on December 9, 2014, is generally directed to a non-invasive neuromodulation therapy that includes stimulating the cranial nerves found in the mouth while the patient is engaged simultaneously in physical movement.
“These issued broad patents relate to rehabilitation of brain function while engaging in physical movement. They are key to defining the PoNS™ as a device that, with approval, will enable both the neurologist and physiotherapist to optimize care for the neurology patient,” said Philippe Deschamps, Chief Executive Officer of Helius.
Helius continues to aggressively protect the PoNS™ technology and related therapies. This USPTO issuance is the second broad patent Helius has received related to the PoNSTM device and the associated therapeutic modality. The first PoNSTM patent, US Patent No. 8,849,407, was issued on September 30, 2014. The Company recently filed more than two dozen patent applications directed towards valuable technical features and ornamental design elements of the PoNSTM device. Helius expects to file additional patent applications to protect its technology, designs and therapeutic methods as they evolve.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology company focused on neurological wellness. The Company’s mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. Helius intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
- US Investor Relations: Todd James (646) email@example.com
- Canadian Investor Relations: (778) 588-7144 firstname.lastname@example.org
- Corporate Contact: Phil Deschamps (614) email@example.com
- Media Contact: Becky Kern (914) 772-2310 firstname.lastname@example.org
Cautionary Disclaimer Statement
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Safe Harbor Statement
All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.